SCHEDULE: Baker Bros. Advisors Boosts Replimune Stake

Baker Bros. Advisors LP and its affiliates have disclosed an increased beneficial ownership in Replimune Group, Inc. following a recent public offering.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the 'Reporting Persons') have filed an amendment to their Schedule 13D, reporting their beneficial ownership of Replimune Group, Inc. common stock.
• The filing details the acquisition of pre-funded warrants in Replimune's public offering on August 9, 2026, which closed on August 11, 2026.
• Baker Bros. entities purchased 2,736,340 pre-funded warrants for an aggregate price of $32,999,986.77.
• The Reporting Persons collectively hold 11,075,336 shares of common stock, representing 11.8% of the outstanding shares.
• The filing also notes a Director Lock-Up Agreement for Michael Goller, restricting the sale of his shares until September 24, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting significant investment activity and strategic positioning by Baker Bros. Advisors, though it also highlights potential dilution and ongoing market dynamics.

Positives

• Significant investment by Baker Bros. Advisors, indicating confidence in Replimune's prospects.
• Acquisition of 2,736,340 pre-funded warrants, totaling $32,999,986.77, demonstrates substantial capital commitment.
• Reporting Persons now beneficially own 11.8% of Replimune's outstanding common stock, solidifying their position as a major shareholder.

Negatives

• The acquisition of pre-funded warrants, while strategic, could lead to future dilution if exercised.
• Beneficial ownership is subject to 'maximum percentage' limitations (4.99% for $0.0001 warrants and 9.99% for $0.001 warrants), restricting immediate exercise and full control.
• A lock-up agreement restricts a director's ability to sell shares until September 24, 2026, potentially limiting immediate market liquidity for those shares.

Risks

• Future exercise of pre-funded warrants could dilute existing shareholders' ownership percentage.
• The 'maximum percentage' limitations on warrant exercise mean that the Reporting Persons cannot immediately convert all their warrants into common stock.
• Changes in market conditions, Replimune's business prospects, or economic factors could lead the Reporting Persons to alter their investment strategy, potentially impacting share price.

Future Outlook

The Reporting Persons may purchase additional securities or dispose of securities at varying times based on assessments of market conditions, Replimune's business prospects, and other investment opportunities. They may also discuss strategic items with the Issuer's management and other investors, potentially influencing future financing or acquisitions.

Management Comments

• The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities.
• The Reporting Persons may discuss items of mutual interest with the Issuer's management and other investors, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
• Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, exercise of $0.0001 Prefunded Warrants (as defined in Item 5), exercise of $0.001 Prefunded Warrants (as defined in Item 5), exercise of Stock Options (as defined in Item 5) or otherwise) or to dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control.

Industry Context

StockSavvy.ai notes that this filing reflects a common strategy among institutional investors like Baker Bros. Advisors to increase or maintain significant stakes in biotechnology companies through public offerings, often utilizing pre-funded warrants to manage immediate capital outlay and ownership percentage.

Stakeholder Impact

• Shareholders may experience dilution if pre-funded warrants are exercised.
• The significant stake held by Baker Bros. Advisors may influence corporate governance decisions and strategic direction.
• The lock-up agreement for Michael Goller temporarily restricts the sale of his shares, potentially affecting market liquidity for a portion of the stock.

Next Steps

• Reporting Persons may purchase additional securities or dispose of securities based on ongoing assessments.
• Reporting Persons may engage in discussions with Issuer's management and other investors regarding strategic matters.
• The exercise of pre-funded warrants is subject to beneficial ownership limitations, with potential adjustments to these limits requiring 61 days' notice.

Key Dates

Recommendation

The filing indicates a substantial investment by a key institutional player, suggesting continued confidence in Replimune. However, the presence of pre-funded warrants with exercise limitations and the ongoing nature of strategic discussions warrant a 'hold' position, allowing for further observation of warrant exercise and strategic developments.

Keywords

Replimune Group, Baker Bros. Advisors, Schedule 13D, Pre-funded Warrants, Beneficial Ownership, Public Offering, Investment Strategy, Lock-Up Agreement